Pharma Pioneer

Sangamo Presents Positive Phase 1/2 Gene Therapy Data for Fabry Disease

31 May 2024
2 min read

Sangamo Therapeutics, a genomic medicine firm, has reported positive interim results from its Phase 1/2 STAAR clinical trial for isaralgagene civaparvovec (ST-920), a gene therapy for Fabry disease. The treatment has shown sustained elevated α-Gal A activity for up to three years in the longest-treated patient, with all 12 patients withdrawn from enzyme replacement therapy (ERT) maintaining this elevated activity for up to 19 months. Antibodies against α-Gal A have significantly decreased in patients with ERT-associated antibodies at baseline, becoming undetectable in five patients. Among 13 patients monitored for over a year, renal function was stable, and improvements were noted in disease severity, quality of life, and gastrointestinal symptoms. The therapy demonstrated a favorable safety profile, with no post-treatment liver function test elevations requiring steroids. Enrollment in the Phase 1/2 study is complete, with dosing of remaining patients expected in the first half of 2024. Sangamo continues discussions with the U.S. FDA and other health authorities regarding registration pathways. The data will be presented at the 20th Annual WORLDSymposium in San Diego on February 7, 2024.

The Phase 1/2 STAAR study is an open-label, single-dose, dose-ranging, multicenter clinical trial assessing the safety and tolerability of ST-920 in Fabry disease patients. The study includes patients on ERT, ERT pseudo-naïve, or ERT-naïve. ST-920 has received Orphan Drug, Fast Track, and RMAT designations from the FDA and Orphan Medicinal Product designation from the European Medicines Agency.

Fabry disease is a lysosomal storage disorder caused by a deficiency in the α-Gal A enzyme, leading to a buildup of Gb3 in cells and damage to vital organs. Symptoms include decreased sweat production, heat intolerance, kidney disease, heart failure, gastrointestinal issues, and neuropathic pain.

Sangamo Therapeutics is focused on developing genomic medicines for serious neurological disorders without adequate treatment options. The company's zinc finger epigenetic regulators and capsid discovery platform aim to address these disorders and expand delivery beyond current intrathecal delivery capsids, including in the central nervous system.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

ProLynx Launches Phase I/II Trial of DNA-Damaging PLX038 for Rare CNS Tumors at NCI
Pharma Pioneer
3 min read
ProLynx Launches Phase I/II Trial of DNA-Damaging PLX038 for Rare CNS Tumors at NCI
31 May 2024
ProLynx Inc. initiated a Phase I/II clinical study involving PLX038, a PEGylated form of SN-38, for treating primary central nervous system (CNS) tumors with MYC or MYCN gene amplifications.
Read →
ProfoundBio Initiates Phase 1/2 Trial for PTK7-Targeted ADC PRO1107
Pharma Pioneer
2 min read
ProfoundBio Initiates Phase 1/2 Trial for PTK7-Targeted ADC PRO1107
31 May 2024
ProfoundBio has launched the Phase 1/2 clinical trial for PRO1107, marking a significant step in their mission to enhance patient outcomes.
Read →
Rani Therapeutics Reports Positive Phase 1 Results for Oral Anti-IL 12/23 Antibody (RT-111)
Pharma Pioneer
2 min read
Rani Therapeutics Reports Positive Phase 1 Results for Oral Anti-IL 12/23 Antibody (RT-111)
31 May 2024
Rani Therapeutics Holdings, Inc. reported encouraging topline results from its Phase 1 clinical trial of RT-111, a RaniPill® capsule containing an ustekinumab biosimilar (CT-P43).
Read →
Triumvira Begins Phase I/II Trial for TAC101-CLDN18.2 Solid Tumor Therapy
Pharma Pioneer
3 min read
Triumvira Begins Phase I/II Trial for TAC101-CLDN18.2 Solid Tumor Therapy
31 May 2024
This study is focused on evaluating the safety and effectiveness of TAC101-CLDN18.2, an advanced cell therapy that utilizes genetically modified autologous T cells.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.